Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd. (QNTM) generates news across clinical development, capital markets, licensing, and legal proceedings, reflecting its role as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse disorders. Many of its recent announcements center on Lucid-21-302 (Lucid-MS), a patented new chemical entity developed through its subsidiary Lucid Psycheceuticals Inc. News items describe progress in toxicity and toxicokinetic studies, Phase 1 clinical work, and preparations for an Investigational New Drug (IND) application with the U.S. FDA, as well as a joint PET imaging study with Massachusetts General Hospital scientists to monitor myelin integrity in multiple sclerosis.
Investors following QNTM news will also see updates on financial results, balance sheet developments, and capital structure changes, including private placements, warrant expirations, at-the-market offering agreements, and the issuance of contingent value rights (CVRs) linked to potential recoveries from litigation. The company’s disclosures highlight its digital asset portfolio, comprised mainly of Bitcoin and other cryptocurrencies, and provide commentary on realized gains and treasury management.
Another recurring theme in Quantum BioPharma’s news flow is its relationship with Unbuzzd Wellness Inc., licensee of the unbuzzd asset. Press releases cover Unbuzzd Wellness Inc.’s capital raising plans, investor webinars, and positioning of unbuzzd as a beverage or supplement aimed at alcohol metabolism and related symptoms, while noting Quantum BioPharma’s equity stake and royalty rights.
In addition, Quantum BioPharma issues updates on its lawsuit alleging stock market manipulation and stock spoofing involving major financial institutions, including coverage by investigative news program W5. These items outline the company’s allegations, the scale of the claimed damages, and the link between the litigation and the CVR structure. For readers and investors, the QNTM news stream offers a consolidated view of clinical milestones, financial reporting, licensing activity, and legal developments related to Quantum BioPharma.
Quantum BioPharma (NASDAQ:QNTM, CSE:QNTM, FRA:0K91), a biopharmaceutical company focused on innovative assets and biotech solutions, has announced its participation in the ArcStone-Kingswood Growth Summit on September 26, 2024, in Toronto, ON. Jason Sawyer, Head of Finance and Mergers and Acquisitions, will present at the event, which features over 30 public and private companies and 47 sponsors from around the world.
The presentation is scheduled for 2:45 p.m. to 2:55 p.m., followed by a 2-minute Q&A session. Mr. Sawyer will discuss the company's growth potential and connect with key investors. The summit aims to create meaningful public companies that drive value for both management and investors. It will be held at the Sheraton Hotel in downtown Toronto.
Quantum BioPharma (NASDAQ: QNTM) has closed a non-brokered private placement, issuing 6 Class A multiple voting shares at $6.00 each for gross proceeds of $36.00. The offering involved related-party transactions with insiders Xorax Family Trust and Fortius Research and Trading Corp. Following the offering, Xorax now owns 50% of outstanding Class A Shares and 34.28% of voting rights, while Fortius owns 50% of outstanding Class A Shares and 34.06% of voting rights. The company plans to use the proceeds for general working capital purposes. The transaction was exempt from formal valuation and minority shareholder approval requirements under MI 61-101.
Quantum BioPharma (NASDAQ:QNTM) has signed an agreement with Ingenu CRO Pty to conduct a clinical study observing disease progression in patients with primary progressive multiple sclerosis. The study, announced on September 9, 2024, will be carried out through Quantum's subsidiary, HUGE Biopharma Australia Pty This observational study is a important step towards initiating a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS), advancing Quantum's multiple sclerosis research program. Dr. Andrzej Chruscinski, VP of Scientific and Clinical Affairs at Quantum Biopharma, expressed enthusiasm about the collaboration, highlighting its importance in progressing their MS research efforts.
Quantum BioPharma (NASDAQ:QNTM) has regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on the exchange. The company has also completed debt settlements of $450,000 each with three executives through the issuance of 248,160 Class B Shares at $5.44 per share. Additionally, Quantum BioPharma announced a non-brokered private placement of up to 6 Class A Shares at $6.00 per share, expected to be subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz. This offering aims to increase Class A Share voting rights to 64.13%. The company also granted 12,500 stock options and 7,500 RSUs to a director and consultants, and cancelled 7,692 warrants previously granted to a board member.
Quantum BioPharma (NASDAQ:QNTM) announces the launch of unbuzzd™, a revolutionary alcohol recovery product, on Amazon.com. Developed by Celly Nutrition, backed by Quantum BioPharma's R&D team, unbuzzd™ is designed to accelerate alcohol metabolism and promote faster recovery. The product is led by CEO John Duffy, former Coca-Cola executive, and co-chaired by Gerry David, former CEO of Celsius Holdings.
unbuzzd™ utilizes a proprietary blend of vitamins, minerals, and herbs to restore mental clarity and hydration. The leadership team includes Kevin Harrington, Original Shark on Shark Tank, and Dr. Eric Hoskins, former Minister of Health for Ontario, Canada. This launch marks a significant step in innovative alcohol recovery solutions, offering consumers a convenient way to manage the aftermath of alcohol consumption.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), formerly FSD Pharma Inc., has completed its name change and 65:1 share consolidation. The company's Class B subordinate voting shares will trade under the new ticker symbol 'QNTM' on NASDAQ and CSE. After consolidation, Class B shares reduced from 84,531,149 to approximately 1,300,727, while Class A multiple voting shares decreased from 72 to 2.
The company also closed a non-brokered private placement, issuing 4 post-consolidation Class A Multiple Voting Shares at $18.00 each for gross proceeds of $72.00. Insiders Xorax Family Trust and Fortius Research and Trading Corp. purchased all Class A shares in this offering, which is considered a related-party transaction under MI 61-101.